Veracyte Board Adds Two New Members

Veracyte Inc. has appointed Brent Shafer and Tom Miller, Ph.D., to its Board of Directors.
 
“We are thrilled to welcome Brent and Tom to our board,” Veracyte CEO Marc Stapley said. “They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board’s mix of backgrounds and expertise.”
 
Shafer has more than 40 years of experience in health information technologies, medical devices, and various healthcare solutions. He previously served as chairman and CEO of Cerner Corporation and CEO of Philips North America and Philips Home Healthcare Solutions. Before that, he served in a variety of roles at Hillrom, GE Medical Systems and Johnson & Johnson. Upon joining the board, Shafer will serve on the Compensation Committee.

“I am thrilled to join the Veracyte board to support the management team in advancing their vision,” Shafer stated. “I look forward to leveraging my experience to help accelerate the momentum underway at Veracyte with their focus on empowering physicians with the high-value insights they need to best serve patients.”
 
Dr. Miller is a scientist and entrepreneur with a focus on the nexus of artificial intelligence (AI), chemistry, and biology. He co-founded and is CEO of Iambic Therapeutics, a biotechnology company that is disrupting the therapeutics landscape with an AI-driven, drug discovery platform. Before that, he spent more than10 years as a tenured professor at Caltech, publishing over 140 peer-reviewed articles and patents. Upon joining the board, Dr. Miller will serve on the Regulatory and Compliance Committee.
 
“It’s an honor to be a part of a company with such a compelling platform and that is so well-positioned to positively impact the journey of so many cancer patients,” Dr. Miller commented. “I am particularly excited by the company’s increased investment in AI as part of their focus on helping clinicians, researchers and patients gain even further ground on cancer.”
 
Veracyte is a global diagnostics company aiming to transform cancer care. The company empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Its Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for tests, along with new insights to support continued innovation and pipeline development.